Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19451549 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Conditions: Metastatic Cancer;   Metastatic Melanoma
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR

Indicates status has not been verified in more than two years